Nausea, vomiting, a feeling of fullness
Therefore, drugs that target these mechanisms, such as GLP-1 RAs, might have beneficial effects in both diseases. Daniel Truong, MD In some studies, the prevalence of Parkinsons disease was lower among patients with diabetes who were treated with glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 inhibitors, which increase GLP-1 levels, than among patients who received other diabetes medications, Truong said
Another thing that makes Ozempic dangerous is that it can cause a persons stomach muscles to stop contracting altogether
Type III and IV individuals demonstrate visible darkening within 1421 days but continue deepening through week 8
Delayed Gastric Emptying: Slowing down the digestive process to prolong the sense of fullness after eating
This efficacy suggests the drug could be suitable for patients with greater weight loss needs, including as an alternative to more invasive treatments like bariatric surgery